205 related articles for article (PubMed ID: 24140761)
1. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.
Morgan CL; Emery P; Porter D; Reynolds A; Young A; Boyd H; Poole CD; Currie CJ
Rheumatology (Oxford); 2014 Jan; 53(1):186-94. PubMed ID: 24140761
[TBL] [Abstract][Full Text] [Related]
2. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs.
Emery P; Gallo G; Boyd H; Morgan CL; Currie CJ; Poole CD; Nab HW
Clin Exp Rheumatol; 2014; 32(5):653-60. PubMed ID: 25190189
[TBL] [Abstract][Full Text] [Related]
3. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
5. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Tanaka Y; Yamanaka H; Hirose T; Yoshinaga T; Suzukawa M
J Rheumatol; 2013 Oct; 40(10):1658-68. PubMed ID: 23908446
[TBL] [Abstract][Full Text] [Related]
7. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
[TBL] [Abstract][Full Text] [Related]
9. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
[TBL] [Abstract][Full Text] [Related]
10. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial.
Kim HY; Hsu PN; Barba M; Sulaiman W; Robertson D; Vlahos B; Khandker R; Nab H; Freundlich B; Koenig A
Int J Rheum Dis; 2012 Apr; 15(2):188-96. PubMed ID: 22462423
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
13. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
15. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
[TBL] [Abstract][Full Text] [Related]
16. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
Davies R; Galloway JB; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Ann Rheum Dis; 2011 Oct; 70(10):1831-4. PubMed ID: 21784722
[TBL] [Abstract][Full Text] [Related]
17. Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: a nationwide population-based cohort study.
Chen HH; Chen DY; Lai KL; Chen YM; Chou YJ; Chou P; Lin CH; Huang N
J Clin Rheumatol; 2013 Dec; 19(8):432-8. PubMed ID: 24263145
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate.
Koyama Y; Shiraishi H; Ohta T; Uchino A
Mod Rheumatol; 2012 Feb; 22(1):100-8. PubMed ID: 21706263
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
20. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
